Granules India Limited (NSE:GRANULES)
738.00
+2.70 (0.37%)
May 15, 2026, 3:30 PM IST
Granules India Employees
Granules India had 4,066 employees as of March 31, 2025. The number of employees increased by 9 or 0.22% compared to the previous year.
Employees
4,066
Change (1Y)
9
Growth (1Y)
0.22%
Revenue / Employee
13.20M INR
Profits / Employee
1.46M INR
Market Cap
181.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 4,066 | 9 | 0.22% |
| Mar 31, 2024 | 4,057 | 407 | 11.15% |
| Mar 31, 2023 | 3,650 | -36 | -0.98% |
| Mar 31, 2022 | 3,686 | 317 | 9.41% |
| Mar 31, 2021 | 3,369 | 340 | 11.22% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Alembic Pharmaceuticals | 16,571 |
| Ajanta Pharma | 9,628 |
| Emcure Pharmaceuticals | 6,731 |
| Piramal Pharma | 5,476 |
| Gland Pharma | 4,351 |
| NATCO Pharma | 4,199 |
| Eris Lifesciences | 3,354 |
| Strides Pharma Science | 3,301 |
Granules India News
- 18 days ago - Granules India Transcript: Q4 25/26 - Transcripts
- 18 days ago - Granules India reports 23% YoY revenue growth in Q4FY26 - Business Upturn
- 6 weeks ago - Granules India completes cGMP audit at Chantilly site with four FDA observations - Business Upturn
- 6 weeks ago - Granules India subsidiary receives VAI classification after US FDA inspection - Business Upturn
- 7 weeks ago - Top stocks to buy today: Stock recommendations for March 27, 2026 - check list - The Times of India
- 2 months ago - Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14% - Business Upturn
- 2 months ago - Pharma sector stocks surge today, March 10: Natco Pharma up 4%, Granules India jumps 3.31%, Glenmark Pharma rises 2.72% - Business Upturn
- 2 months ago - Granules India subsidiary receives US FDA EIR with NAI status for Virginia facility - Business Upturn